# Development of a novel product for skin decontamination after exposure to chemical warfare agents

> **NIH NIH R44** · ARMIS BIOPHARMA, INC. · 2020 · $423,048

## Abstract

ABSTRACT
With the increasing threat of terrorism, the development of countermeasures for the event of a chemical attack
on civilians has become a high priority. Mass casualty events in which chemical warfare agents (CWA) would be
employed in an attack on a civilian population, are a concrete risk. Because of significant differences between
members of the military and civilians, existing countermeasures may need to be adapted or expanded for use in
a civilian population. This project proposes the development of Veriox®, a proprietary formulation, to provide first
responders working on mass-casualty decontamination (DC) an inexpensive, FDA approved, fast-acting, field-
deployable skin decontamination kit that would provide superior levels of protection when compared to the
current field-deployed products. Veriox® offers several advantages over existing DC products for mass casualty
settings, because it can be rapidly dispensed with standard liquid dispensing systems (hand operated sprayers
and mass casualty shower systems) that will allow first responders to quickly decontaminate multiple individuals.
Last but not least, since Veriox® breaks down rapidly into harmless products, it demonstrates a better safety and
toxicity profile, and is also environmentally safe. While Veriox® is a potentially broad-spectrum decontaminant,
with efficacy shown already against Generating Antibiotic Incentives Now (GAIN) Act pathogens, this project
focuses on its development in the context of nerve agent decontamination. We present a strong background of
preliminary studies demonstrating efficacy in vivo. The next step of the development program is to demonstrate
safety of the product in animals which will then enable advancement of the product into human testing. This is
the focus of the present grant.

## Key facts

- **NIH application ID:** 10080358
- **Project number:** 1R44NS119085-01
- **Recipient organization:** ARMIS BIOPHARMA, INC.
- **Principal Investigator:** Scott Noblitt
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $423,048
- **Award type:** 1
- **Project period:** 2020-09-15 → 2022-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10080358

## Citation

> US National Institutes of Health, RePORTER application 10080358, Development of a novel product for skin decontamination after exposure to chemical warfare agents (1R44NS119085-01). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10080358. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*